Download PDF
Thorac Cardiovasc Surg 2004; 52(4): 237-248
DOI: 10.1055/s-2004-817843
Review

© Georg Thieme Verlag KG Stuttgart · New York

Biological Bypass in Cardiovascular Surgery

G. Lutter1 , R. Quaden1 , J. Cremer1
  • 1Department of Cardiovascular Surgery, Christian-Albrecht University of Kiel, School of Medicine, Kiel, Germany
Further Information

Publication History

Received January 5, 2004

Publication Date:
04 August 2004 (online)

    Permissions and Reprints All articles of this category

Abstract

Protein and gene therapy offer a tremendous opportunity to improve the care of critically ill patients with ischemic heart and peripheral artery occlusion disease. With the availability of purified growth factors such as vascular endothelial and fibroblast growth factors (FGF), several experimental and clinical studies provided data, that the growth of capillaries (angiogenesis) and of collateral arteries (arteriogenesis) is not limited to its natural time course. When applied in experimental models and in conjunction with coronary artery bypass operations, FGF in particular, led to a significant increase in endogenous rerouting of blood flow by collateral vessels inside the tissue itself. Thus, the proliferation of preexisting bypassing arterioles could be enhanced therapeutically (biological bypass). The purpose of this review is to discuss the physiological importance of different kinds of cytokines which are able to induce angio- and arteriogenesis in ischemic limbs or the heart. It is outlined that a combination of a sufficient amount of large arterioles and a capillary network are needed to compensate perfusion deficits. Each patient, who has an ischemic area and cannot be conventionally revascularized, is a potential candidate for the biological bypass.

Key words

Angiogenesis - therapeutic angiogenesis - arteriogenesis - collaterals - FGF - VEGF - transmyocardial laser revascularization - blood flow

References

  • 1 Ruel M, Sellke F W. Angiogenic protein therapy.  Semin Thorac Cardiovasc Surg. 2003;  15 222-235
    PubMedGoogle Scholar
  • 2 Cohn W E, Ruel M, Zhang J P, Sellke F W, Johnson R G. Internal thoracic artery flow competition: studies in a canine H-graft model.  Eur J Cardiothorac Surg. 2003;  23 56-59
    CrossrefPubMedGoogle Scholar
  • 3 Ruel M, Wu G F, Khan T A, Voisine P, Bianchi C, Li J, Li J, Laham R J, Sellke F W. Inhibition of the cardiac angiogenic response to surgical FGF-2 therapy in a swine endothelial dysfunction model.  Circulation. 2003;  108 (Suppl 1) II335-340
    PubMedGoogle Scholar
  • 4 Rohen J W, Lütjen-Drecoll E. Zirkulationssystem. Rohen JW, Lütjen-Drecoll E Funktionelle Histologie. Stuttgart; Schattauer 2000: 147-176
    Google Scholar
  • 5 Torres Filho I P, Kerger H, Intaglietta M. pO2 measurements in arteriolar networks.  Microvasc Res. 1996;  51 202-212
    PubMedGoogle Scholar
  • 6 Risau W. Mechanisms of angiogenesis.  Nature. 1997;  386 671-674
    CrossrefPubMedGoogle Scholar
  • 7 Schaper W, Buschmann I. Arteriogenesis, the good and the bad of it.  Cardiovasc Res. 1999;  43 835-837
    CrossrefPubMedGoogle Scholar
  • 8 Folkman J. Therapeutic angiogenesis in ischemic limbs.  Circulation. 1998;  97 1108-1110
    PubMedGoogle Scholar
  • 9 Xie Z, Gao M, Batra S, Koyama T. The capillarity of left ventricular tissue of rats subjected to coronary artery occlusion.  Cardiovasc Res. 1997;  33 671-676
    CrossrefPubMedGoogle Scholar
  • 10 Schaper W. Coronary collateral development: concepts and hypotheses. Schaper W, Schaper J Collateral Circulation. Dortrecht, Norwell; Kluwer Academic Publishers 1993: 41-64
    Google Scholar
  • 11 Scholz D, Ito W, Fleming I. et al . Ultrastructure and molecular histology of rabbit hind-limb collateral artery growth (arteriogenesis).  Virchows Arch. 2000;  436 257-270
    CrossrefPubMedGoogle Scholar
  • 12 Zimmermann R, Arras M, Ullmann C. et al . Time course of mitosis and collateral growth following coronary microembolization in the porcine heart.  Cell Tissue Res. 1997;  287 583-590
    CrossrefPubMedGoogle Scholar
  • 13 Lutter G, Martin J, Dern P. et al . Evaluation of the indirect revascularization method after 3 months chronic myocardial ischemia.  Eur J Cardiothorac Surg. 2000;  18 38-45
    CrossrefPubMedGoogle Scholar
  • 14 Takeshita S, Isshiki T, Ochiai M. et al . Endothelium-dependent relaxation of collateral microvessels after intramuscular gene transfer of vascular endothelial growth factor in a rat model of hindlimb ischemia.  Circulation. 1998;  98 1261-1263
    PubMedGoogle Scholar
  • 15 Lee S H, Wolf P L, Escudero R, Deutsch R, Jamieson S W, Thistlethwaite P A. Early expression of angiogenesis factors in acute myocardial ischemia and infarction.  N Engl J Med. 2000;  342 626-633
    CrossrefPubMedGoogle Scholar
  • 16 Hasdai D, Barak V, Leibovitz E. et al . Serum basic fibroblast growth factor levels in patients with ischemic heart disease.  Int J Cardiol. 1997;  59 133-138
    CrossrefPubMedGoogle Scholar
  • 17 Rohovsky S, Kearney M, Pieczek A. et al . Elevated levels of basic fibroblast growth factor in patients with limb ischemia.  Am Heart J. 1996;  132 1015-1019
    CrossrefPubMedGoogle Scholar
  • 18 Fleisch M, Billinger M, Eberli F R, Garachemani A R, Meier B, Seiler C. Physiologically assessed coronary collateral flow and intracoronary growth factor concentrations in patients with 1- to 3-vessel coronary artery disease.  Circulation. 1999;  100 1945-1950
    PubMedGoogle Scholar
  • 19 Mandriota S J, Pepper M S. Vascular endothelial growth factor-induced in vitro angiogenesis and plasminogen activator expression are dependent on endogenous basic fibrolast growth factor.  J Cell Sci. 1997;  110 2293-2302
    PubMedGoogle Scholar
  • 20 Resnick N, Collins T, Atkinson W, Bonthron D T, Dewey Jr C F, Gimbrone Jr M A. Platelet-derived growth factor B chain promoter contains a cis-acting fluid shear-stress-responsive element.  Proc Natl Acad Sci USA. 1993;  90 4591-4595
    PubMedGoogle Scholar
  • 21 Venema R C, Nishida K, Alexander R W, Harrison D G, Murphy T J. Organization of the bovine gene encoding the endothelial nitric oxide synthase.  Biochem Biophys Acta. 1994;  1218 413-420
    PubMedGoogle Scholar
  • 22 Li C, Xu Q. Mechanical stress-initiated signal tranductions in vascular smooth muscle cells.  Cell Signal. 2000;  12 435
    CrossrefPubMedGoogle Scholar
  • 23 Laguens R, Cabeza Meckert P, Crottogini A. Entrance in mitosis of adult cardiomyocytes in ischemic pig hearts after plasmid-mediated rhVEGF165 gene transfer.  Gene Ther. 2002;  9 1676-1681
    CrossrefPubMedGoogle Scholar
  • 24 Nabel E G, Plautz G, Nabel G J. Site-specific gene expression in vivo by direct gene transfer into the arterial wall.  Science. 1990;  249 1285-1288
    PubMedGoogle Scholar
  • 25 Lin S J, Jan K M, Chien S. Temporal and spatial changes in macromolecular uptake in rat thoracic aorta and relation to [3 H]thymidine uptake.  Atherosclerosis. 1990;  85 229-238
    PubMedGoogle Scholar
  • 26 Acsadi G, Jiao S S, Jani A, Duke D, Williams P, Chong W, Wolff J A. Direct gene transfer and expression into rat heart in vivo.  New Biol. 1991;  3 71-81
    PubMedGoogle Scholar
  • 27 Jeong J O. et al . Improved expression by cytomegalovirus promoter/enhancer and behavior of vascular endothelial growth factor gene after myocardial injection of naked DNA.  Exp Mol Med. 2002;  34 278-284
    PubMedGoogle Scholar
  • 28 Morishita R. et al . Recent progress in gene therapy for cardiovascular disease.  Circ J. 2002;  66 1077-1086
    CrossrefPubMedGoogle Scholar
  • 29 Santiago F S, Khachigian L M. Nucleic acid based strategies as potential therapeutic tools: mechanistic considerations and implications to restenosis.  J Mol Med. 2001;  79 695-706 [E-pub Sep 22, 2001]
    CrossrefPubMedGoogle Scholar
  • 30 Simons M, Edelman E R, Rosenberg R D. Antisense proliferating cell nuclear antigen oligonucleotides inhibit intimal hyperplasia in a rat carotid artery injury model.  J Clin Invest. 1994;  93 2351-2356
    PubMedGoogle Scholar
  • 31 Zhu N L, Wu L, Liu P X, Gordon E M, Anderson W F, Starnes V A, Hall F L. Downregulation of cyclin G1 expression by retrovirus-mediated antisense gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation.  Circulation. 1997;  96 628-635
    PubMedGoogle Scholar
  • 32 Qin L, Pahud D R, Ding Y, Bielinska A U, Kukowska-Latallo J F, Baker Jr J R, Bromberg J S. Efficient transfer of genes into murine cardiac grafts by Starburst polyamidoamine dendrimers.  Hum Gene Ther. 1998;  9 553-560
    PubMedGoogle Scholar
  • 33 Perletti G, Marras E, Dondi D. Assessment of the biological activity of an improved naked-DNA vector for angiogenesis gene therapy on a novel non-mammalian model.  Int J Mol Med. 2003;  11 691-696
    PubMedGoogle Scholar
  • 34 Arsic N, Zentilin L, Zacchigna S. Induction of functional neovascularization by combined VEGF and angiopoietin-1 gene transfer using AAV vectors.  Mol Ther. 2003;  7 450-459
    CrossrefPubMedGoogle Scholar
  • 35 Harvey B G, Hackett N R, El-Sawy T. et al . Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs.  J Virol. 1999;  73 6729-6742
    PubMedGoogle Scholar
  • 36 Newman K D, Dunn P F, Owens J W. et al . Adenovirus-mediated gene transfer into normal rabbit arteries results in prolonged vascular cell activation, inflammation, and neointimal hyperplasia.  J Clin Invest. 1995;  96 2955-2965
    PubMedGoogle Scholar
  • 37 Eslami M H, Gangadharan S P, Sui X X, Rhynhart K K, Snyder R O, Conte M S. Gene delivery to in situ veins: differential effects of adenovirus and adeno-associated viral vectors.  J Vasc Surg. 2000;  31 1149-1159
    PubMedGoogle Scholar
  • 38 Baumgartner I, Isner J. Somatic gene therapy in the cardiovascular system.  Annu Rev Physiol. 2001;  63 427-450
    CrossrefPubMedGoogle Scholar
  • 39 Carmeliet P, Ferreira V, Breier G. et al . Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele.  Nature. 1996;  380 435-439
    CrossrefPubMedGoogle Scholar
  • 40 Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors.  FASEB J. 1999;  13 9-22
    PubMedGoogle Scholar
  • 41 Gowdak L HW, Poliakova L, Wang X. et al . Adenovirus-mediated VEGF121 gene transfer stimulates angiogenesis in normoperfused skeletal muscle and preserves tissue perfusion after induction of ischemia.  Circulation. 2000;  102 565-571
    PubMedGoogle Scholar
  • 42 Schwarz E R, Speakman M T, Patterson M. et al . Evaluation of the effects of intramyocardial injection of DNA expressing vascular endothelial growth factor (VEGF) in a mycardial infarction model in the rat - angiogenesis and angioma formation.  J Am Coll Cardiol. 2000;  35 1323-1330
    CrossrefPubMedGoogle Scholar
  • 43 Lee R J, Springer M L, Blanco-Bose W E. et al . VEGF gene delivery to myocardium. Deleterious effects of unregulated expression.  Circulation. 2000;  102 898-901
    PubMedGoogle Scholar
  • 44 Eslami M H, Gangadharan S P, Sui X X, Rhynhart K K, Snyder R O, Conte M S. Gene delivery to in situ veins: differential effects of adenovirus and adeno-associated viral vectors.  J Vasc Surg. 2000;  31 1149-1159
    PubMedGoogle Scholar
  • 45 Takeshita S, Tsurumi Y, Couffinahl T. et al . Gene transfer of naked DNA encoding for three isoforms of vascular endothelial growth factor stimulates collateral development in vivo.  Lab Invest. 1996;  75 487-501
    PubMedGoogle Scholar
  • 46 Takeshita S, Isshiki T, Ochiai M. et al . Endothelium-dependent relaxation of collateral microvessels after intramuscular gene transfer of vascular endothelial growth factor in a rat model of hindlimb ischemia.  Circulation. 1998;  98 1261-1263
    PubMedGoogle Scholar
  • 47 Asahara T, Takahashi T, Matsuda H. et al . VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells.  EMBO J. 1999;  18 3964-3972
    CrossrefPubMedGoogle Scholar
  • 48 Baumgartner I, Pieczek A, Manor O. et al . Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia.  Circulation. 1998;  97 1114-1123
    CrossrefPubMedGoogle Scholar
  • 49 Baumgartner I, Rauh G, Pieczek A. et al . Lower-extremity edema associated with gene transfer of naked DNA encoding vascular endothelial growth factor.  Ann Intern Med. 2000;  132 880-884
    PubMedGoogle Scholar
  • 50 Thurston G, Rudge J S, Ioffe E. et al . Angiopoietin-1 protects the adult vasculature against plasma leakage.  Nat Med. 2000;  6 460-463
    CrossrefPubMedGoogle Scholar
  • 51 Pepper M S, Vassalli J D, Orci L, Montesano R. Biphasic effect of transforming growth factor-beta 1 on in vitro angiogenesis.  Exp Cell Res. 1993;  204 356-363
    CrossrefPubMedGoogle Scholar
  • 52 Brogi E, Wu T, Namiki A, Isner J M. Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only.  Circulation. 1994;  90 649-652
    CrossrefPubMedGoogle Scholar
  • 53 Stavri G T, Hong Y, Zachary I C. et al . Hypoxia and platelet-derived growth factor-BB synergistically upregulate the expression of vascular endothelial growth in vascular smooth muscle cells.  FEBS Lett. 1995;  358 311-315
    CrossrefPubMedGoogle Scholar
  • 54 Khan T A, Sellke F W, Laham R J. Gene therapy progress and prospects: therapeutic angiogenesis for limb and myocardial ischemia.  Gene Ther. 2003;  10 285-291
    CrossrefPubMedGoogle Scholar
  • 55 Bianchi R, Rodella L, Rezzani R. Cyclosporine A upregulates expression of matrix metalloproteinase 2 and vascular endothelial growth factor in rat heart.  Int Immunopharmacol. 2003;  3 427-433
    PubMedGoogle Scholar
  • 56 Mehrabi M R. et al . Clinical benefit of prostaglandin E1-treatment of patients with ischemic heart disease: stimulation of therapeutic angiogenesis in vital and infarcted myocardium.  Biomed Pharmacother. 2003;  57 173-178
    CrossrefPubMedGoogle Scholar
  • 57 Symes J F, Losordo D W, Vale P R, Lathi K G, Esakof D D, Mayskiy M, Isner J M. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease.  Ann Thorac Surg. 1999;  68 830-836 discussion 836-837
    CrossrefPubMedGoogle Scholar
  • 58 Rivard A, Silver M, Chen D. et al . Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF.  Am J Pathol. 1999;  154 355-363
    PubMedGoogle Scholar
  • 59 Waltenberger J, Lange J, Kranz A. Vascular endothelial growth factor-A-induced chemotaxis of monocytes is attenuated in patients with diabetes mellitus.  Circulation. 2000;  102 185-190
    PubMedGoogle Scholar
  • 60 Couffinhal T, Silver M, Kearney M. et al . Impaired collateral vessel development associated with reduced expression of vascular endothelial growth factor in ApoE -/- mice.  Circulation. 1999;  99 3188-3198
    PubMedGoogle Scholar
  • 61 Rivard A, Fabre J E, Silver M. et al . Age-dependent impairment of angiogenesis.  Circulation. 1999;  99 111-120
    PubMedGoogle Scholar
  • 62 Mignatti P, Morimoto T, Rifkin D B. Basic fibroblast growth factor released by single, isolated cells stimulates their migration in an autocrine manner.  Proc Natl Acad Sci USA. 1991;  88 11007-11011
    PubMedGoogle Scholar
  • 63 Montesano R, Vassalli J D, Baird A, Guillemin R, Orci L. Basic fibroblast growth factor induces angiogenesis in vitro.  Proc Natl Acad Sci USA. 1986;  83 7297-7301
    PubMedGoogle Scholar
  • 64 Speir E, Tanner V, Gonzalez A M, Farris J, Baird A, Casscell W. Acidic and basic fibroblast growth factors in adult rat heart myocytes. Localization, regulation in culture, and effects on DNA synthesis.  Circ Res. 1992;  71 251-259
    PubMedGoogle Scholar
  • 65 Sato Y, Rifkin D B. Autocrine activities of basic fibroblast growth factor: regulation of endothelial cell movement, plasminogen activator synthesis, and DNA synthesis.  J Cell Biol. 1988;  107 1199-1205
    CrossrefPubMedGoogle Scholar
  • 66 Walgenbach K J, Gratas C, Shestak K C, Becker D. Ischaemia-induced expression of bFGF in normal skeletal muscle: A potential paracrine mechanism for mediating angiogenesis in ischaemic skeletal muscle.  Nat Med. 1995;  1 453-459
    PubMedGoogle Scholar
  • 67 Chen C H, Jiang W, Via D P. et al . Oxidized low-density lipoproteins inhibit endothelial cell proliferation by suppressing basic Fibroblast Growth Factor expression.  Circulation. 2000;  101 171-177
    PubMedGoogle Scholar
  • 68 Pepper M S, Ferrara N, Orci L, Montesano R. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro.  Biochem Biophys Res Commun. 1992;  189 824-831
    CrossrefPubMedGoogle Scholar
  • 69 Safi Jr J, DiPaula Jr A F, Riccioni T. et al . Adenovirus-mediated acidic fibroblast growth factor gene transfer induces angiogenesis in the non-ischemic rabbit heart.  Microvasc Res. 2000;  58 238-249
    PubMedGoogle Scholar
  • 70 Heilmann C, von Samson P, Schlegel K, Attmann T, von Specht B U, Beyersdorf F, Lutter G. Comparison of protein with DNA therapy for chronic myocardial ischemia using fibroblast growth factor-2.  Eur J Cardiothorac Surg. 2002;  22 957-964
    CrossrefPubMedGoogle Scholar
  • 71 Ninomiya M, Koyama H, Miyata T, Hamada H, Miyatake S, Shigematsu H, Takamoto S. Ex vivo gene transfer of basic fibroblast growth factor improves cardiac function and blood flow in a swine chronic myocardial ischemia model.  Gene Ther. 2003;  10 1152-1160
    CrossrefPubMedGoogle Scholar
  • 72 Schumacher B, Pecher P, von Specht B U, Stegmann T. Induction of neoangiogenesis in ischemic myocardium by human growth factors. First clinical results of a new treatment of coronary heart disease.  Circulation. 1998;  97 645-650
    PubMedGoogle Scholar
  • 73 Pecher P, Schumacher B A. Angiogenesis in ischemic human myocardium: clinical results after 3 years.  Ann Thorac Surg. 2000;  69 1414-1419
    CrossrefPubMedGoogle Scholar
  • 74 Kastrup J. Therapeutic angiogenesis in ischemic heart disease: gene or recombinant vascular growth factor protein therapy?.  Curr Gene Ther. 2003;  3 197-206
    PubMedGoogle Scholar
  • 75 Goede V, Brogelli L, Ziche M, Augustin H G. et al . Induction of inflammatory angiogenesis by monocyte chemoattractant protein-1.  Int J Cancer. 1999;  82 765-770
    CrossrefPubMedGoogle Scholar
  • 76 Behr T M, Wang X, Aiyar N. et al . Monocyte chemoattractant protein-1 is upregulated in rats with volume-overload congestive heart failure.  Circulation. 2000;  102 1315-1322
    PubMedGoogle Scholar
  • 77 Yoshimura T, Yuhki N, Moore S K, Appella E, Lerman M I, Leonard E J. Human monocyte chemoattractant protein-1 (MCP-1). Full-length cDNA cloning, expression in mitogen-stimulated blood mononuclear leukocytes, and sequence similarity to mouse competence gene JE.  FEBS Lett. 1989;  244 487-493
    CrossrefPubMedGoogle Scholar
  • 78 Denger S, Jahn L, Wende P. et al . Expression of monocyte chemoattractant protein-1 cDNA in vascular smooth muscle cells: induction of the synthetic phenotype: a possible clue to SMC differentiation in the process of atherogenesis.  Atherosclerosis. 1999;  144 15-23
    CrossrefPubMedGoogle Scholar
  • 79 Schaper W. Coronary collateral development: concepts and hypotheses. Schaper W, Schaper J Collateral Circulation. Dortrecht, Norwell; Kluwer Academic Publishers 1993: 41-64
    Google Scholar
  • 80 Marumo T, Schini-Kerth V B, Busse R. Vascular endothelial growth factor activates nuclear factor-kappaB and induces monocyte chemoattractant protein-1 in bovine retinal endothelial cells.  Diabetes. 1999;  48 1131-1137
    PubMedGoogle Scholar
  • 81 Wempe F, Lindner V, Augustin H G. Basic fibroblast growth factor (bFGF) regulates the expression of the CC chemokine monocyte chemoattractant protein-1 in autocrine-activated endothelial cells.  Arterioscler Thromb Vasc Biol. 1997;  17 2471-2478
    PubMedGoogle Scholar
  • 82 Ito W D, Arras M, Winkler B, Scholz D, Schaper J, Schaper W. Monocyte chemotactic protein-1 increases collateral and peripheral conductance after femoral artery occlusion.  Circ Res. 1997;  80 829-837
    CrossrefPubMedGoogle Scholar
  • 83 Heilmann C A, Attmann T, Thiem A, Haffner E, Beyersdorf F, Lutter G. Gene therapy in cardiac surgery: intramyocardial injection of naked plasmid DANN for chronic myocardial ischemia.  Eur J Cardiothorac Surg. 2003;  24 785-793
    CrossrefPubMedGoogle Scholar
  • 84 Weidner K M, Arakaki N, Hartmann G. et al . Evidence for the identity of human scatter factor and human hepatocyte growth factor.  PNAS. 1991;  88 7001-7005
    PubMedGoogle Scholar
  • 85 Grant D S, Kleinman H K, Goldberg I D. et al . Scatter factor induces blood vessel formation in vivo.  PNAS. 1993;  90 1937-1941
    PubMedGoogle Scholar
  • 86 Gherardi E, Gray J, Stoker M, Perryman M, Furlong R. Purification of scatter factor, a fibroblast-derived basic protein that modulates epithelial interactions and movement.  PNAS. 1989;  86 5844-5848
    PubMedGoogle Scholar
  • 87 Roletto F, Galvani A P, Cristiani C, Valsasina B, Landonio A, Bertolero F. Basic fibroblast growth factor stimulates hepatocyte growth factor/scatter factor secretion by human mesenchymal cells.  J Cell Physiol. 1996;  166 105-111
    CrossrefPubMedGoogle Scholar
  • 88 Hayashi S, Morishita R, Nakamura S. et al . Potential role of hepatocyte growth factor, a novel angiogenic growth factor, in peripheral arterial disease.  Circulation. 1999;  100 II301-II308
    PubMedGoogle Scholar
  • 89 Morishita R, Nakamura S, Hayashi S. et al . Therapeutic angiogenesis induced by human recombinant hepatocyte growth factor in rabbit hind limb ischemia model as cytokine supplement therapy.  Hypertension. 1999;  33 1379-1384
    PubMedGoogle Scholar
  • 90 Aoki M, Morishita R, Taniyama Y. et al . Angiogenesis induced by hepatocyte growth factor in non-infarcted myocardium and infarcted myocardium: up-regulation of essential transcription factor for angiogenesis, ets.  Gene Therapy. 2000;  7 417-427
    CrossrefPubMedGoogle Scholar
  • 91 Suzuki H. et al . Hepatocyte growth factor and vascular endothelial growth factor in ischaemic heart disease.  Coron Artery Dis. 2003;  14 301-307
    CrossrefPubMedGoogle Scholar
  • 92 Li J, Brown L F, Hibberd M G, Grossman J D, Morgan J P, Simons M. VEGF, flk-1, and flt-1 expression in a rat myocardial infarction model of angiogenesis.  Am J Physiol. 1996;  270 H1803-1811
    PubMedGoogle Scholar
  • 93 Van Belle E, Witzenbichler B, Chen D. et al . Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor.  Circulation. 1998;  97 381-390
    PubMedGoogle Scholar
  • 94 Shyu K G, Manor O, Magner M, Yancopoulos G D, Isner J M. Direct intramuscular injection of plasmid DNA encoding angiopoietin-1 but not angiopoietin-2 augments revascularization in the rabbit ischemic hindlimb.  Circulation. 1998;  98 2081-2087
    PubMedGoogle Scholar
  • 95 Asahara T, Chen D, Takahashi T. et al . Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization.  Circ Res. 1998;  83 233-240
    PubMedGoogle Scholar
  • 96 Asahara T, Takahashi T, Matsuda H. et al . VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells.  EMBO J. 1999;  18 3964-3972
    CrossrefPubMedGoogle Scholar
  • 97 Valenzuela D M, Griffiths J A, Rojas J. et al . Angiopoietins 3 and 4: diverging gene counterparts in mice and humans.  PNAS. 1999;  96 1904-1909
    CrossrefPubMedGoogle Scholar
  • 98 Li J, Brown L F, Hibberd M G, Grossman J D, Morgan J P, Simons M. VEGF, flk-1, and flt-1 expression in a rat myocardial infarction model of angiogenesis.  Am J Physiol. 1996;  270 H1803-1811
    PubMedGoogle Scholar
  • 99 Shen H, Clauss M, Ryan J. et al . Characterization of vascular permeability factor/vascular endothelial growth factor receptors on mononuclear phagocytes.  Blood. 1993;  81 2767-2773
    PubMedGoogle Scholar
  • 100 Sharma H S, Wunsch M, Brand T, Verdouw P D, Schaper W. Molecular biology of the coronary vascular and myocardial responses to ischemia.  J Cardiovasc Pharmacol. 1992;  20 S23-31
    PubMedGoogle Scholar
  • 101 Chung N A, Makin A J, Lip G Y. Measurement of the soluble angiopoietin receptor tie-2 in patients with coronary artery disease: development and application of an immunoassay.  Eur J Clin Invest. 2003;  33 529-535
    CrossrefPubMedGoogle Scholar
  • 102 Baumgartner I, Pieczek A, Manor O. et al . Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia.  Circulation. 1998;  97 1114-1123
    CrossrefPubMedGoogle Scholar
  • 103 Frazier O H, March R J, Horvath K A. Transmyocardial revascularization with a carbon dioxide laser in patients with end-stage coronary artery disease.  N Engl J Med. 1999;  341 1021-1028
    CrossrefPubMedGoogle Scholar
  • 104 Lutter G, Schwarzkopf J, Lutz C, Martin J, Beyersdorf F. Histologic findings of transmyocardial laser channels after two hours.  Ann Thorac Surg. 1998;  65 1437-1439
    CrossrefPubMedGoogle Scholar
  • 105 Lutter G, Martin J, Dern P. et al . Evaluation of the indirect revascularization method after 3 months chronic myocardial ischemia.  Eur J Cardiothorac Surg. 2000;  18 38-45
    CrossrefPubMedGoogle Scholar
  • 106 Horvath K A, Chiun E, Maun D C. et al . Up-regulation of vascular endothelial growth factor mRNA and angiogenesis after transmyocardial laser revascularization.  Ann Thorac Surg. 1999;  68 825-829
    CrossrefPubMedGoogle Scholar
  • 107 Pelletier M P, Giaid A, Sivaraman S. et al . Angiogenesis and growth factor expression in a model of transmyocadial revascularization.  Ann Thorac Surg. 1998;  66 12-18
    CrossrefPubMedGoogle Scholar
  • 108 Chiang B B, Roberts A M, Kashem A M. et al . Chemoreflexes: an experimental study.  Arch Surg. 2000;  135 577-581
    PubMedGoogle Scholar
  • 109 Morishita R, Nakamura S, Hayashi S. et al . Therapeutic angiogenesis induced by human recombinant hepatocyte growth factor in rabbit hind limb ischemia model as cytokine supplement therapy.  Hypertension. 1999;  33 1379-1384
    PubMedGoogle Scholar
  • 110 Asahara T, Chen D, Takahashi T. et al . Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization.  Circ Res. 1998;  83 233-240
    PubMedGoogle Scholar
  • 111 Lutter G, Sarai K, Nitzsche E. et al . Evaluation of transmyocardial laser revascularization by following objective parameters of perfusion and ventricular function.  Thorac Cardiov Surg. 2000;  48 79-85
    PubMedGoogle Scholar
  • 112 Valenzuela D M, Griffiths J A, Rojas J. et al . Angiopoietins 3 and 4: diverging gene counterparts in mice and humans.  PNAS. 1999;  96 1904-1909
    CrossrefPubMedGoogle Scholar
  • 113 Tjomsland O, Aaberge L, Almdahl S M. et al . Perioperative cardiac function and predictors for adverse events after transmyocardial laser treatment.  Ann Thorac Surg. 2000;  69 1098-1103
    CrossrefPubMedGoogle Scholar
  • 114 Pelletier M P, Giaid A, Sivaraman S. et al . Angiogenesis and growth factor expression in a model of transmyocadial revascularization.  Ann Thorac Surg. 1998;  66 12-18
    CrossrefPubMedGoogle Scholar
  • 115 Sayeed-Shah U. et al . Complete reversal of ischemic wall motion abnormalities by combined use of gene therapy with transmyocardial laser revascularization.  J Thorac Cardiovasc Surg. 1998;  116 763-769
    PubMedGoogle Scholar
  • 116 Heilmann C A, Attmann T, von Samson P, Gobel H, Marme D, Beyersdorf F, Lutter G. Transmyocardial laser revascularization combined with vascular endothelial growth factor 121 (VEGF121) gene therapy for chronic myocardial ischemia - do the effects really add up?.  Eur J Cardiothorac Surg. 2003;  23 74-80
    CrossrefPubMedGoogle Scholar
  • 117 Lutter G, Attmann T, Heilmann C, von Samson P, von Specht B, Beyersdorf F. The combined use of transmyocardial laser revascularization (TMLR) and fibroblastic growth factor (FGF-2) enhances perfusion and regional contractility in chronically ischemic porcine hearts.  Eur J Cardiothorac Surg. 2002;  22 753-761
    CrossrefPubMedGoogle Scholar
  • 118 Peichev M, Naiyer A J, Pereira D. et al . Expression of VEGFR-2 and AC133 by circulating CD34+ cells identifies a population of functional endothelial precursors.  Blood. 2000;  95 952-958
    PubMedGoogle Scholar
  • 119 Kalka C, Masuda H, Takahashi T. et al . Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization.  PNAS. 2000;  97 3422-3427
    CrossrefPubMedGoogle Scholar
  • 120 Kawamoto A, Gwon H C, Iwaguro H, Yamaguchi J I, Uchida S, Masuda H, Silver M, Ma H, Kearney M, Isner J M, Asahara T. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia.  Circulation. 2001;  103 634-637
    PubMedGoogle Scholar
  • 121 Iwaguro H, Yamaguchi J, Kalka C, Murasawa S, Masuda H, Hayashi S, Silver M, Li T, Isner J M, Asahara T. Endothelial progenitor cell vascular endothelial growth factor gene transfer for vascular regeneration.  Circulation. 2002;  105 732-738
    CrossrefPubMedGoogle Scholar
  • 122 Pearlman J D, Laham L J, Simons M. Coronary angiogenesis: detection in vivo with MR imaging sensitive to collateral neocirculation - preliminary study in pigs.  Radiology. 2000;  214 801-807
    PubMedGoogle Scholar
  • 123 Takeshita S, Isshiki T, Mori H. et al . Microangiographic assessment of collateral vessel formation following direct gene transfer of vascular endothelial growth factor in rats.  Cardiovasc Res. 1997;  35 547-552
    CrossrefPubMedGoogle Scholar
  • 124 Beighley P E, Thomas P J, Jorgensen S M, Ritman E L. 3 D architecture of myocardial microcirculation in intact rat heart: a study with micro-CT.  Adv Exp Med Biol. 1997;  430 165-175
    PubMedGoogle Scholar
  • 125 Mills J D, Fischer D, Villanueva F S. Coronary collateral development during chronic ischemia: serial assessment using harmonic myocardial contrast echocardiography.  J Am Coll Cardiol. 2000;  36 618-624
    CrossrefPubMedGoogle Scholar
  • 126 Hedman M. et al . Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT).  Circulation. 2003;  107 2677-2683
    CrossrefPubMedGoogle Scholar
  • 127 Diaz-Sandoval L J, Losordo D W. Gene therapy for cardiovascular angiogenesis.  Expert Opin Biol Ther. 2003;  3 599-616
    CrossrefPubMedGoogle Scholar

M. D. Georg Lutter

Department of Cardiovascular Surgery · Christian-Albrecht University Kiel · School of Medicine

Arnold-Heller-Straße 7

24105 Kiel

Germany

Phone: + 494315974582

Fax: + 49 43 15 97 44 02

Email: lutter@kielheart.uni-kiel.de